In the randomized phase II AdvanTIG-203 trial, adding the anti-TIGIT antibody ociperlimab to tislelizumab did not significantly improve response rates or survival in advanced esophageal squamous cell carcinoma. The negative result narrows the window for TIGIT-based combinations in this setting. The outcome matters for teams exploring next-generation checkpoint pairings, since success in esophageal cancer has been uneven and depends heavily on patient selection and biomarker strategy. The trial also underscores the high bar for demonstrating survival benefit when combining immune pathways. For biotech developers, the data informs go/no-go decisions on similar immuno-oncology combinations.